"During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Smith Giri, University of Alabama at Birmingham, Birmingham, US. We asked, Can daratumumab overcome the negative prognostic impact of high-risk cytogenetics?
In this video, Smith Giri describes the efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics from a meta-analysis of pooled phase III randomized trials. This study compared backbone myeloma regimens with or without daratumumab in either the frontline or relapsed/refractory setting. These trials included the CASSIOPEIA and CASTOR studies"d.
https://buff.ly/38Y8ssJ
In this video, Smith Giri describes the efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics from a meta-analysis of pooled phase III randomized trials. This study compared backbone myeloma regimens with or without daratumumab in either the frontline or relapsed/refractory setting. These trials included the CASSIOPEIA and CASTOR studies"d.
https://buff.ly/38Y8ssJ
